ERBB2 and breast carcinoma: As with anti-HER2 therapies in HER2-amplified breast cancer, moving targeted HER family therapies earlier, to the adjuvant setting, when tumor burden is low and the pool of dividing tumor cells that can acquire new mutations is small, may well result in improved outcomes [69].